From the team that developed the words first medically licensed ENDS comes RespaLABS a company dedicated to the development of safer nicotine delivery designed for adult smokers.

RespaLABS is committed to developing the safest inhaled nicotine products and building the science to support modified risk claims under the MRTPA pathway.

Using novel, patented technology, RespaLABS uses low temperature aerosilization to effectively deliver nicotine for adult smokers. RespaLABS developments are supported by years of studies including pharmacokinetic studies demonstrating effective and safe delivery of nicotine.